Appl. No. 09/846,346 Amdt. dated Reply to Office action of May 17, 2005

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

Claim 1. (withdrawn) An isolated biopolymer marker consisting of SEQ ID NO:1.

Claims 2-35. (cancelled)

Claim 36. (currently amended) A method for determining the presence of an isolated a biopolymer marker having SEQ ID NO:1 and a molecular weight of about 1998 daltons comprising:

- (a) obtaining a sample from a patient;
- (b) conducting mass spectrometric analysis on said sample in a manner effective to maximize diversity of biopolymers analysis of peptide fragments contained therein and comparing a mass spectrum profiles profile of [[said]] a isolated biopolymer marker having SEQ ID NO:1 and a molecular weight of about 1998 daltons to mass spectrum profiles of peptides biopolymers obtained and analyzed from said sample; and
 - (c) confirming the presence of [[said]] a isolated biopolymer

Appl. No. 09/846,346 Amdt. dated Reply to Office action of May 17, 2005

marker having SEQ ID NO:1 and a molecular weight of about 1998

daltons in said sample displaying a peak profile at about 1998

daltons in said mass spectrum profile;

wherein the presence of said isolated biopolymer marker having SEQ ID NO:1 and a molecular weight of about 1998 daltons is indicative of a link to Type II diabetes.

Claim 37. (currently amended) The method of claim 36, wherein [[the]] said sample is an unfractionated body fluid or a tissue sample.

Claim 38. (previously presented) The method of claim 36, wherein said sample is selected from the group consisting of blood, blood products, urine, saliva, cerebrospinal fluid, and lymph.

Claim 39. (previously presented) The method of claim 36, wherein said mass spectrometric analysis is Surface Enhanced Laser Desorption Ionization (SELDI) mass spectrometry (MS).

Claim 40. (previously presented) The method of claim 36, wherein said patient is a human.

Claim 41. (withdrawn) A Type II diabetes diagnostic kit comprising: (a) a peptide consisting of SEQ ID NO:1 and (b) an

Appl. No. 09/846,346 Amdt. dated Reply to Office action of May 17, 2005

antibody that binds to said peptide in a sample from a patient.

Claim 42. (withdrawn) The diagnostic kit of claim 41, wherein said antibody is immobilized on a solid support.

Claim 43. (withdrawn) The diagnostic kit of claim 41, wherein said antibody is labeled.